AC Immune SA filings document a foreign private issuer developing precision therapeutics and diagnostics for neurodegenerative diseases. Recent Form 6-K reports furnish press releases, IFRS financial statements, management discussion and annual statutory and compensation reports, with certain reports incorporated by reference into Form F-3 and Form S-8 registration statements.
The disclosures cover clinical and trial updates for ACI-24, ACI-7104.056, ACI-19764 and ACI-35.030/JNJ-2056; collaboration amendments for Morphomer® Tau small molecules; cash resources and operating requirements; and governance-related compensation reporting. They also record exhibit-based material updates for AC Immune’s active immunotherapy, small-molecule and diagnostic pipeline.
AC Immune SA director Monika Buetler received new equity awards as part of her compensation. On June 11, 2026, she was granted 17,751 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan. The grant increases her direct interest in the company without any cash purchase.
On the same date, she also received share options for 41,667 common shares at an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. After these awards, she directly holds 71,656 common shares, largely reflecting restricted share units rather than open-market buying.
AC Immune SA director June Carl Howard reported new equity compensation grants. On June 11, 2026, she received 16,568 common shares as a restricted share unit grant under the AC Immune SA 2016 Stock Option and Incentive Plan.
Following this award, her direct holdings in common shares were 67,556. She also received share options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036. These awards reflect compensation rather than open‑market trading.
AC Immune SA reported that shareholders approved all proposals at the June 2026 Annual General Meeting, including the 2025 IFRS consolidated and statutory financial statements and the 2025 compensation report. Shareholders also discharged the Board and Executive Management and approved maximum compensation of CHF 1.029M for the Board and CHF 6.742M for Executive Management.
The company recorded a 2025 IFRS loss of CHF 70.4M on revenue of CHF 3.6M, increasing accumulated losses brought forward to CHF 424.441M. Liquidity was CHF 91.4M at year-end 2025 and CHF 74.8M as of March 31, 2026, supporting guidance for a cash runway into Q4 2027 with 2026 cash burn of CHF 55–65M. Shareholders approved a new capital band allowing share capital changes between CHF 2,202,018.50 and CHF 2,862,500.00 until June 11, 2031, and increased conditional share capital for employee plans to CHF 150,000.00 (up to 7.5 million shares). The AGM presentation highlighted an Alzheimer’s and Parkinson’s-focused pipeline, multiple FDA Fast Track designations and planned 2026 clinical milestones.
AC Immune SA reported that it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. The funding will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, its anti‑alpha‑synuclein active immunotherapy, in early Parkinson’s disease.
The company highlights that the extended trial will help generate long‑term safety and efficacy data, particularly for prodromal and early Parkinson’s disease where prolonged treatment is expected. Management describes ACI‑7104 as showing promising interim Phase 2 results with favorable safety, strong antibody responses, target engagement and encouraging clinical signals, with final Part 1 data to week‑104 expected in H2 2026.
AC Immune SA Chief Executive Officer Andrea Pfeifer reported an open-market sale of 10,000 common shares. The trade occurred on May 15, 2026 at a weighted average price of $2.7935 per share, with individual prices ranging from $2.75 to $2.825.
After this sale, Pfeifer directly holds 3,820,288 common shares, which include 1,921,005 common shares underlying outstanding restricted share units. She also reports 14,000 common shares held indirectly by her spouse.
ACIU affiliate files Form 144 to sell 20,000 common shares. The filing lists 20,000 shares proposed for sale and references prior 10b5-1 sales of 10,000 shares on 02/17/2026, 03/16/2026 and 04/15/2026 with the listed proceeds per sale. The notice identifies the shares as previously exercised stock options.
AC Immune SA has called its 2026 Annual General Meeting for 11 June 2026 and published the invitation and proxy materials. Shareholders will vote on approval of the 2025 IFRS consolidated and statutory financial statements, the 2025 compensation report, loss appropriation, discharge of directors and executives, and binding maximum compensation for the Board and Executive Management.
The Board proposes Board compensation up to CHF 1,029,000 for the term from the 2026 AGM to the 2027 AGM and Executive Management compensation up to CHF 6,742,000 for 2027. Under IFRS, the consolidated net loss for 2025 was CHF 70,447K, with accumulated losses carried forward.
CEO Andrea Pfeifer will retire at the 2026 AGM after 23 years, and Chair Martin Zügel will serve as Interim CEO while remaining Chair. To reinforce governance, the Board appointed Monika Bütler as Lead Independent Director and added Carl June to the Audit & Finance Committee. Shareholders will also vote on introducing a capital band between CHF 2,202,018.50 and CHF 2,862,500.00 and increasing conditional share capital for employee plans to 7,500,000 shares.
AC Immune SA announced that co-founder and long-serving Chief Executive Officer Dr Andrea Pfeifer plans to retire at the Annual General Meeting on June 11, 2026 to spend more time with her family. The company states her decision is not due to any disagreement over operations, policies, or practices.
The Board has appointed its Chair, Dr Martin Zügel, as interim CEO while a search firm leads the process to identify a permanent successor. Dr Pfeifer will remain closely involved as Advisor, Honorary Chair of the Board, and Co-Chair of the Scientific Advisory Board, supporting leadership continuity as AC Immune advances its neurodegenerative disease pipeline and partnerships.
AC Immune SA reported first quarter 2026 results showing it remains a clinical-stage company investing heavily in neurodegenerative disease programs. Contract revenue was CHF 1.1 million, while the Company recorded a net loss of CHF 14.8 million, improving from a CHF 19.0 million loss a year earlier as research and development and general and administrative expenses declined.
As of March 31, 2026, AC Immune held CHF 19.2 million in cash and cash equivalents and CHF 55.6 million in short-term financial assets. The Company states its cash resources are expected to provide sufficient capital to last into Q4 2027, excluding potential milestone payments. Management highlighted progress in collaborations with Takeda and Eli Lilly and pointed to multiple anticipated 2026 clinical milestones across its Alzheimer’s and Parkinson’s disease pipelines.
AC Immune SA reported that it has dosed the first patients in Cohort AD4, the final planned cohort in its ongoing Phase 1b/2 ABATE trial of ACI-24, an anti-Abeta active immunotherapy for Alzheimer’s disease. Reaching this trial milestone triggers a $12 million payment from partner Takeda under their exclusive, worldwide option and license agreement for active immunotherapies targeting toxic amyloid beta.
The ABATE trial is evaluating ACI-24 in people with prodromal Alzheimer’s disease and adults with Down syndrome. Earlier cohorts AD1–AD3 enrolled 74 patients at escalating doses, with 12‑month data readouts expected later in Q2 2026. AD4 will initially enroll 36 patients treated for 12 months plus 6 months of follow-up, and may be expanded to about 112 subjects, substantially enlarging the safety and biomarker data set for ACI-24.
AC Immune highlights that ACI-24 has so far been generally safe and well tolerated, with anti-Abeta antibody responses observed at all tested doses and no safety concerns raised by multiple data safety monitoring board reviews. Under the Takeda agreement, AC Immune previously received $100 million upfront and remains eligible for an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1 billion, plus tiered double-digit royalties on any worldwide net sales.